Logo
x

Search

Subscribe Now

prostate cancer

Laekna’s LAE002(Afuresertib) + LAE001 Receives FDA Approval for P-III Trial Protocol to Treat Prostate Cancer

Laekna’s LAE002(Afuresertib) + LAE001 Receives FDA Approval for P-III Trial Protocol to Treat Prostate Cancer

  • May 24, 2024
PharmaShots Interview: Q BioMed's Denis Corin Shares Insights on the Agreement to Serve US Department of Defense and Veterans Affairs

PharmaShots Interview: Q BioMed's Denis Corin Shares Insights on the Agreement to Serve US Department of Defense and Veterans Affa...

  • July 13, 2021
Lantheus' Pylarify (piflufolastat F 18) Injection Receives the US FDA's Approval for the Treatment of Prostate Cancer

Lantheus' Pylarify (piflufolastat F 18) Injection Receives the US FDA's Approval for the Treatment of Prostate Cancer

  • May 27, 2021
PharmaShots Interview: Myriad Genetics' Dr. Todd D. Cohen Shares Insight on Prolaris Test's Ability to Guide Prostate Cancer Treatment

PharmaShots Interview: Myriad Genetics' Dr. Todd D. Cohen Shares Insight on Prolaris Test's Ability to Guide Prostate Cancer Treat...

  • March 25, 2021
The US FDA Approves Gallium 68 PSMA-11 as the First PSMA-Targeted PET Imaging Drug for Men with Prostate Cancer

The US FDA Approves Gallium 68 PSMA-11 as the First PSMA-Targeted PET Imaging Drug for Men with Prostate Cancer

  • December 1, 2020
Janssen Receives EC's Approval for Expanded Use of Erleada (apalutamide) to Treat Metastatic Hormone-Sensitive Prostate Cancer

Janssen Receives EC's Approval for Expanded Use of Erleada (apalutamide) to Treat Metastatic Hormone-Sensitive Prostate Cancer

  • January 30, 2020
Bayer Reports the Regulatory Submission of Nubeqa (Darolutamide) to the EMA for Treating Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

    Bayer Reports the Regulatory Submission of Nubeqa (Darolutamide) to the EMA for Treating Metastatic Hormone-Sensitive Prostate Can...

    • October 14, 2024
    Johnson & Johnson Highlights the Real-World Study of Erleada (Apalutamide) for Treating Metastatic Castration-Sensitive Prostate Cancer at ECOP 2024

      Johnson & Johnson Highlights the Real-World Study of Erleada (Apalutamide) for Treating Metastatic Castration-Sensitive Prostate C...

      • October 3, 2024
      Bayer Reports Regulatory Submission of Nubeqa to the US FDA for Treating Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

        Bayer Reports Regulatory Submission of Nubeqa to the US FDA for Treating Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

        • September 26, 2024
        Astellas at ASCO 2024: Ahsan Arozullah in an Illuminating Dialogue Exchange with PharmaShots

          Astellas at ASCO 2024: Ahsan Arozullah in an Illuminating Dialogue Exchange with PharmaShots

          • September 16, 2024
          Bayer Provides Update on P-III (ARANOTE) Study of Darolutamide to Treat Metastatic Hormone-Sensitive Prostate Cancer

            Bayer Provides Update on P-III (ARANOTE) Study of Darolutamide to Treat Metastatic Hormone-Sensitive Prostate Cancer

            • July 17, 2024
            Full-Life Technologies’ 225Ac-FL-020 Gains the US FDA’s Fast Track Designation to Treat Metastatic Castration-Resistant Prostate Cancer

              Full-Life Technologies’ 225Ac-FL-020 Gains the US FDA’s Fast Track Designation to Treat Metastatic Castration-Resistant Prostate C...

              • July 4, 2024
              Image

              Incisive News in 3 Shots.

              Contact Us

              Our Information

              Follow Us

              Copyright © 2025 PharmaShots - All Rights Reserved.